Latest Us Growth News

Ansell has entered FY27 with stronger margins, cash generation and shareholder distributions after adjusted EBIT rose 14.9% organically in FY26. The PPE maker is maintaining adjusted EPS guidance of 158 to 170 US cents while targeting further growth from US markets, productivity and a simpler product range.

QuickFee’s Q1 FY27 revenue held at A$4.2 million on a normalised basis, while US loan originations rose 15% and Australian transaction values slipped. The lender maintained FY27 EBTDA guidance at A$4.5 million to A$5.0 million despite lower net interest margins and softer SME conditions.

Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.

PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.

Latrobe Magnesium has completed its fully underwritten $3.4 million entitlement offer, with sub-underwriters absorbing roughly 91% of the available shares. The company says the funding carries its Victorian demonstration plant through to targeted first magnesium production by the end of 2026.

Zip delivered strong first-quarter growth, with total transaction volume up 18% to A$4.6 billion, but a US fraud event cost A$10.1 million and pushed group net bad debts higher. The company nevertheless reaffirmed its A$340 million FY27 cash EBTDA target, with September momentum offering an early test of whether the disruption was temporary.

Airtasker delivered its strongest GMV growth in four years in FY26, but the expansion still consumed cash as international investment accelerated. The ASX-listed marketplace is now targeting positive free cash flow in FY27 while scaling membership and reducing UK investment.

Airtasker’s Australian marketplace reached a record $57.3 million in first-quarter GMV, while paid subscribers more than doubled in three months. The company reaffirmed FY27 guidance as international growth continued, though seasonal weakness is expected in the UK and US.

ARB Corporation’s FY26 profit fell 5.2% as weaker Australian aftermarket and OEM sales outweighed modest export growth. The 4x4 accessories maker is relying on improved vehicle supply, US expansion and new product programs to rebuild momentum in FY27.

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.

Volt Resources has secured US$5.4 million in fully government-funded support for its US graphite refinery and customer application centre. The award is positive for project funding, but the company’s ASX securities remain suspended as it works with the exchange to satisfy reinstatement requirements.

Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.